Evidence for medicinal cannabis ‘limited’, review finds

Warning message

The subscription service is currently unavailable. Please try again later.

Evidence for the efficacy of medicinal cannabis is scarce, and a system to regulate it would be challenging and costly, but there would be therapeutic benefit for specific patient groups.

 

In a review published in Australian Prescriber today, Bridin Murnion — senior staff specialist in drug health services at Royal Prince Alfred Hospital in Sydney and clinical senior lecturer in addiction medicine at Sydney University — says the debate must be kept distinct from the one over recreational marijuana.

The two most studied components of cannabis are THC (the psychoactive ingredient) and cannabidiol. Currently the only cannabis product on the Australian Register of Therapeutic Goods is nabiximols, a combination of THC and cannabidiol, which can be prescribed for multiple sclerosis.

The review found modest evidence of benefit of one or the other or both in multiple sclerosis muscle spasms, HIV-related weight loss, and pain associated with cancer, HIV neuropathy and rheumatoid...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.